PT  - JOURNAL ARTICLE
AU  - Jadvar, Hossein
AU  - Colletti, Patick M.
TI  - Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy
AID  - 10.2967/jnmt.122.264928
DP  - 2023 Jan 01
TA  - Journal of Nuclear Medicine Technology
PG  - jnmt.122.264928
4099  - http://tech.snmjournals.org/content/early/2023/01/04/jnmt.122.264928.short
4100  - http://tech.snmjournals.org/content/early/2023/01/04/jnmt.122.264928.full
AB  - Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA-11, 18F-DCFPyL) and radiopharmaceutical therapy (177Lu-PSMA-617) have paved the way for theranostics as a viable care strategy for men with metastatic castration-resistant prostate cancer. The imaging clinical trials OSPREY, CONDOR and those conducted at the University of California (Los Angeles and San Francisco) as well as the randomized phase 3 therapy trial VISION have been the fruitful beginnings for PSMA theranostics. There are currently several ongoing clinical trials to expand the reach of PSMA theranostics to the earlier phases of prostate cancer and to optimize its utility in combination therapeutic regimens. We provide a brief narrative review of the many PSMA-directed radiopharnaecutical therapy clinical trials with the beta emitter, 177Lu-PSMA-617, and the alpha emitter, 225Ac-PSMA-617, in prostate cancer.